Satellos Bioscience Stock Surges on FDA Fast Track Nod

The FDA’s fast track status is intended to accelerate the development and review of therapies targeting serious conditions where medical needs remain unmet. Satellos is currently testing its candidate, SAT-3247, in Phase 2 clinical trials involving both children and adults.

Frank Gleeson, co-founder and chief executive, stated that the FDA’s decision builds upon previous orphan drug and rare pediatric disease designations. These regulatory recognitions provide a significant boost to the company’s ongoing clinical program as it seeks to address the progression of Duchenne muscular dystrophy.